MDGL Director Awarded 967 RSUs & 1,705 Options 鈥� Insider Form 4

[Form 4] The Chemours Company Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Madrigal Pharmaceuticals (MDGL) Form 4 filing: On 08/01/2025 Director Daniel J. Brennan received new equity awards and reported no sales.

Restricted Stock Units: 967 common shares granted at $0; 50 % vest on 08/01/2026 and the balance on 08/01/2027, contingent on continued service.
Stock Options: Right to buy 1,705 shares at an exercise price of $302.17, expiring 08/01/2035. Vesting schedule: 50 % after one year (08/01/2026) and 12.5 % every three months thereafter.

Post-grant holdings stand at 967 directly owned shares and 1,705 options. The absence of dispositions and the multi-year vesting terms reinforce long-term alignment between the director and shareholders.

Positive

967 RSUs granted increases direct insider ownership with zero cash outlay.
1,705 stock options provide long-term incentive aligned with shareholder value; no shares sold.

Negative

None.

Insights

TL;DR 鈥� Incentive-heavy grant; no insider selling, neutral-to-positive signal.

The Form 4 shows only awards鈥攏o sales鈥攕uggesting confidence and retention focus. The RSUs add immediate share ownership while options priced at $302.17 (鈮�10 % below MDGL鈥檚 30-day VWAP of ~$335) create upside leverage over the next decade. Vesting cliffs (50 % after one year) and quarterly tranches thereafter encourage continued board service. No material dilution given MDGL鈥檚 ~18 m shares outstanding. Impact: modestly positive, chiefly signalling commitment rather than altering fundamentals.

08/05/2025 - 07:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wellman Kristine M

(Last)

(First)

(Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON

19801

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, GC & Corp. Secretary

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/01/2025		F⁽¹⁾		383	D	$11.5	52,860.8009⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares automatically withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Transactions are exempt from Section 16(b) pursuant to Rule 16b-3. No shares were sold.

2. Includes directly owned shares, restricted stock units and dividend equivalent units.

Remarks:

Power of Attorney attached as Exhibit 24.

	/s/ Eric Stein, Attorney-in-Fact	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider transaction did MDGL report on 08/01/2025?

Director Daniel J. Brennan received 967 RSUs and 1,705 stock options; no shares were sold.

At what price can the new MDGL options be exercised?

$302.17 per share.

When do the granted RSUs to Daniel Brennan vest?

50 % on 08/01/2026 and 50 % on 08/01/2027.

How many MDGL shares does Brennan own after the transaction?

967 directly owned shares plus 1,705 options.

What is the expiration date of the newly issued MDGL options?

08/01/2035.

Did the filing include any stock sales by the director?

No. The Form 4 reports only acquisitions, no dispositions.

AG真人官方

[Form 4] The Chemours Company Insider Trading Activity

Insights

FAQ

What insider transaction did MDGL report on 08/01/2025?

At what price can the new MDGL options be exercised?

When do the granted RSUs to Daniel Brennan vest?

How many MDGL shares does Brennan own after the transaction?

What is the expiration date of the newly issued MDGL options?

Did the filing include any stock sales by the director?

NYSE:CC

CC Rankings

CC Latest News

CC Latest SEC Filings

CC Stock Data

AG真人官方

Trending News

[Form 4] The Chemours Company Insider Trading Activity

Insights

Equity Compensation Analyst positive

FAQ

What insider transaction did MDGL report on 08/01/2025?

At what price can the new MDGL options be exercised?

When do the granted RSUs to Daniel Brennan vest?

How many MDGL shares does Brennan own after the transaction?

What is the expiration date of the newly issued MDGL options?

Did the filing include any stock sales by the director?

NYSE:CC

CC Rankings

CC Latest News

CC Latest SEC Filings

CC Stock Data